VericelFRA:ATQP +2.31%72 OCF Margin % is 23.94% as of Mar. 2026, which is 92% above its 10-year median of 12.46. GuruFocus rates FRA:ATQP with a GF Score™ of 72/100 and a GF Value™ of €46.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Vericel ranks better than 84.37% on this metric.
The historical rank and industry rank for Vericel's OCF Margin % or its related term are showing as below:
FRA:ATQP'
s OCF Margin % Range Over the Past 10 Years
Min: -36.58 Med: 12.46 Max: 24.52
Current: 21.1
During the past 13 years, the highest OCF Margin % of Vericel was 24.52%. The lowest was -36.58%. And the median was 12.46%.
FRA:ATQP's OCF Margin % is ranked better than 84.37% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs FRA:ATQP: 21.10
Vericel OCF Margin % Related Terms
Vericel OCF Margin % Historical Data
* Premium members only.
The historical data trend for Vericel's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ATQP vs PVLA, TSHA, GENB: OCF Margin % Comparison
For the Biotechnology subindustry, Vericel's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Vericel's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (FRA:ATQP) has a OCF Margin % of 23.94% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vericel and its competitors. This is 92% above median its historical median of 12.46. According to the industry distribution chart, Vericel ranks #150 out of 960 companies in the Biotechnology industry, placing it in the top 15.6%.
Is Vericel's OCF Margin % too high?
Vericel's current OCF Margin % of 23.94% is 92% above median its 10-year median of 12.46. Based on the distribution chart, Vericel ranks #150 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vericel has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's OCF Margin % compare to PVLA and TSHA?
According to the Biotechnology industry distribution chart, Vericel ranks #150 out of 960 companies for OCF Margin %. This places Vericel in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vericel and its competitors. Vericel's current OCF Margin % is 23.94%, which is 92% above median its own 10-year median of 12.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (FRA:ATQP) is currently considered Modestly Undervalued. The stock's GF Value™ is €46.10, compared to a current price of €35.40 — trading 23.2% below its estimated fair value. The current OCF Margin % is 23.94%, which is 92% above median its 10-year median of 12.46. Vericel's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current OCF Margin % is 23.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (FRA:ATQP) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of €35.40 is trading 23.2% below its estimated GF Value™ of €46.10.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for FRA:ATQP:
OCF Margin %: 23.94% (92% above median its 10-year median of 12.46)
GF Value™: €46.10 vs. price of €35.40 (23.2% below fair value)
No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
72GF Score
Get the complete analysis for FRA:ATQP
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ATQP has been successfully added to your 
